BACKGROUND: Neuronal tissue has a limited potential to self-renew or get repaired after damage. Cell therapies using stem cells are promising approaches for the treatment of central nervous system (CNS) injuries. However, the clinical use of embryonic stem cells is limited by ethical concerns and other scientific consequences. Bone marrow mesenchymal stromal cells (BM-MSC) could represent an alternative source of stem cells for replacement therapy. Indeed, many studies have demonstrated that MSCs can give rise to neuronal cells as well as many tissue-specific cell phenotypes. PURPOSE: Motor recovery by transplantation of bone marrow MSCs in rat models of spinal cord injury (SCI). METHODS: Bone marrow was collected from the femur of albino Wistar rats. MSCs were separated using the Ficoll-Paque density gradient method and cultured in Dulbecco's Modified Eagle Medium supplemented with 20% fetal bovine serum. Cultured MSC was characterized by immunohistochemistry and flow cytometry and neuronal-induced cells were further characterized for neural markers. Cultured MSCs were transplanted into the experimentally injured spinal cord of Wistar rats. Control (injured, but without cell transplantation) and transplanted rats were followed up to 8 weeks, analyzed using the Basso, Beattie, Bresnahan (BBB) scale and electromyography (EMG) for behavioral and physiological status of the injured spinal cord. Finally, the tissue was evaluated histologically. RESULTS: Rat MSCs expressed positivity for a panel of MSC markers CD29, CD54, CD90, CD73, and CD105, and negativity for hematopoietic markers CD34, CD14, and CD45. In vitro neuronal transdifferentiated MSCs express positivity for β III tubulin, MAP2, NF, NeuN, Nav1.1, oligodendrocyte (O4), and negativity for glial fibrillary acid protein. All the treated groups show promising hind-limb motor recovery BBB score, except the control group. There was increased EMG amplitude in treated groups as compared to the control group. Green fluorescent protein (GFP)-labeled MSC survived and differentiated into neurons in the injured spinal cord, which is responsible for functional recovery. CONCLUSION: Our results demonstrate that BM-MSC has the potential to repair the injured cord in rat models of SCI. Thus, BM-MSC appears to be a promising candidate for cell-based therapy in CNS injury.
BACKGROUND: Neuronal tissue has a limited potential to self-renew or get repaired after damage. Cell therapies using stem cells are promising approaches for the treatment of central nervous system (CNS) injuries. However, the clinical use of embryonic stem cells is limited by ethical concerns and other scientific consequences. Bone marrow mesenchymal stromal cells (BM-MSC) could represent an alternative source of stem cells for replacement therapy. Indeed, many studies have demonstrated that MSCs can give rise to neuronal cells as well as many tissue-specific cell phenotypes. PURPOSE: Motor recovery by transplantation of bone marrow MSCs in rat models of spinal cord injury (SCI). METHODS: Bone marrow was collected from the femur of albino Wistar rats. MSCs were separated using the Ficoll-Paque density gradient method and cultured in Dulbecco's Modified Eagle Medium supplemented with 20% fetal bovine serum. Cultured MSC was characterized by immunohistochemistry and flow cytometry and neuronal-induced cells were further characterized for neural markers. Cultured MSCs were transplanted into the experimentally injured spinal cord of Wistar rats. Control (injured, but without cell transplantation) and transplanted rats were followed up to 8 weeks, analyzed using the Basso, Beattie, Bresnahan (BBB) scale and electromyography (EMG) for behavioral and physiological status of the injured spinal cord. Finally, the tissue was evaluated histologically. RESULTS: Rat MSCs expressed positivity for a panel of MSC markers CD29, CD54, CD90, CD73, and CD105, and negativity for hematopoietic markers CD34, CD14, and CD45. In vitro neuronal transdifferentiated MSCs express positivity for β III tubulin, MAP2, NF, NeuN, Nav1.1, oligodendrocyte (O4), and negativity for glial fibrillary acid protein. All the treated groups show promising hind-limb motor recovery BBB score, except the control group. There was increased EMG amplitude in treated groups as compared to the control group. Green fluorescent protein (GFP)-labeled MSC survived and differentiated into neurons in the injured spinal cord, which is responsible for functional recovery. CONCLUSION: Our results demonstrate that BM-MSC has the potential to repair the injured cord in rat models of SCI. Thus, BM-MSC appears to be a promising candidate for cell-based therapy in CNS injury.
Authors: C P Hofstetter; E J Schwarz; D Hess; J Widenfalk; A El Manira; Darwin J Prockop; L Olson Journal: Proc Natl Acad Sci U S A Date: 2002-02-19 Impact factor: 11.205
Authors: R F Pereira; K W Halford; M D O'Hara; D B Leeper; B P Sokolov; M D Pollard; O Bagasra; D J Prockop Journal: Proc Natl Acad Sci U S A Date: 1995-05-23 Impact factor: 11.205
Authors: Francesco P Jori; Marco A Napolitano; Mariarosa A B Melone; Marilena Cipollaro; Antonino Cascino; Lucia Altucci; Gianfranco Peluso; Antonio Giordano; Umberto Galderisi Journal: J Cell Biochem Date: 2005-03-01 Impact factor: 4.429
Authors: Nadia S Mahmoud; Hanaa H Ahmed; Mohamed R Mohamed; Khalda S Amr; Hadeer A Aglan; Mohamed A M Ali; Mohamed A Tantawy Journal: Cytotechnology Date: 2019-11-13 Impact factor: 2.058
Authors: Ravena P do Nascimento; Lívia B de Jesus; Markley S Oliveira-Junior; Aurea M Almeida; Eduardo L T Moreira; Bruno D Paredes; Jorge M David; Bruno S F Souza; Maria de Fátima D Costa; Arthur M Butt; Victor Diogenes A Silva; Silvia L Costa Journal: Front Pharmacol Date: 2022-04-05 Impact factor: 5.988
Authors: Mir Sadat-Ali; Dakheel A Al-Dakheel; Ayesha Ahmed; Haifa A Al-Turki; Abdallah S Al-Omran; Sadananda Acharya; Methal I Al-Bayat Journal: World J Stem Cells Date: 2020-12-26 Impact factor: 5.326